Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro.
Peritoneal macrophages from BD IX rats collected 24 hr after an i.p. injection of ADriamycin (10 mg/kg) were cytotoxic to syngeneic cancer cells in culture. In contrast, incubation in vitro in Adriamycin solutions did not evoke tumoricidal activity in peritoneal macrophages, whatever the incubation time (from 1 to 24 hr) and the Adriamycin concentration (from 1 ng to 100 micrograms/ml). Macrophages incubated with Adriamycin in vitro accumulated the drug in their nuclei, whereas macrophages from animals receiving Adriamycin in vivo accumulated it is cytoplasmic vacuoles. Early observation of peritoneal cells after in vivo exposure to Adriamycin shows that Adriamycin is concentrated in mast cell granules which are released and then phagocytosed by peritoneal macrophages. Mast cells exposed to Adriamycin in vitro can induce macrophages to become cytotoxic. These facts explain the difference between macrophages exposed to Adriamycin in vivo and in vitro. Adriamycin fluorescence appears in nuclei of cancer cells incubated with in vivo-labeled macrophages, suggesting that macrophages can directly transfer the drug into cancer cells and therefore play a role in the Adriamycin antitumor effect.
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology; D002467:Cell Nucleus / Q000378:metabolism; D002470:Cell Survival; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000473:pathology*; D003594:Cytoplasmic Granules / Q000378:metabolism; D004317:Doxorubicin / Q000378:metabolism / Q000494:pharmacology*; D002479:Inclusion Bodies / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D008407:Mast Cells / Q000378:metabolism*; D051381:Rats
D004317:Doxorubicin